http://jcps.bjmu.edu.cn

Journal of Chinese Pharmaceutical Sciences

• Editor profile • Previous Articles     Next Articles

Lihe Zhang, travels on the pharmaceutical road

Donghong Fu, Huiyuan Wu, Shuxiang song   

  • Received:2014-03-01 Revised:2014-03-10 Online:2014-03-13 Published:2014-03-15

Abstract:

Professor Lihe Zhang, Academician of the Chinese Academy, is the founder and research leader on nucleosides and nucleotides, and also a worldwide famous pharmaceutical chemist. Firstly, he served at School of Pharmaceutical Sciences, Peking University Health Science Center as Assistant and Lecturer. From 1981 to 1983, he worked as Research Associate in Department of Chemistry, University of Virginia, USA. Since 1985 he has become a professor and then was designated as Dean of School of Pharmaceutical Sciences, Director of Chemistry Department, National Natural Science Foundation of China, and Director of State Key Laboratory of Natural and Biomimetic Drugs, Peking University. 
      His research interests include Cyclic ADP-ribose (cADPR), a metabolite of NAD+, which is a signaling molecule to regulate calcium mobilization via ryanodine receptors (RyR) from intracellular stores in a wide variety of biological systems. A main approach to explore the molecular mechanism of calcium release is to investigate the relationship of the structure of cADPR and cADPR analogues with their respective biological activities. In addition to the structure activity relationship, such studies result in novel antagonists and agonists which serve as the tools for mechanistic studies in the complex cellular system or potential drug lead. This publication list contains more than 200 original research articles and review papers. For his outstanding works, a serial prizes was awarded to him, such as: National Natural Science Award, Second Prize, Ministry of Science and Technology, China; Millennium Pharmaceutical Scientist Award, FIP, San Francisco, USA; Nagai-Hisamitsu  Outstanding Science Award, Asia Pharmaceutical Association, Kyoto, Japan and so on.

Supporting: